

Joseph Golec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7862847/publications.pdf>

Version: 2024-02-01

17
papers

292
citations

1163117

8
h-index

996975

15
g-index

17
all docs

17
docs citations

17
times ranked

206
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance fee contract change and mutual fund risk. <i>Journal of Financial Economics</i> , 2004, 73, 93-118.	9.0	78
2	Pharmaceutical R&D Spending and Threats of Price Regulation. <i>Journal of Financial and Quantitative Analysis</i> , 2010, 45, 239-264.	3.5	41
3	Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms. <i>Pharmacoeconomics</i> , 2010, 28, 615-628.	3.3	27
4	Do Investors See through Mistakes in Reported Earnings?. <i>Journal of Financial and Quantitative Analysis</i> , 2011, 46, 1917-1946.	3.5	26
5	Using options to measure the full value-effect of an event: Application to Obamacare. <i>Journal of Financial Economics</i> , 2016, 120, 169-193.	9.0	26
6	Mutual fund volatility timing and management fees. <i>Journal of Banking and Finance</i> , 2009, 33, 589-599.	2.9	25
7	Debt Capacity of Real Estate Collateral. <i>Real Estate Economics</i> , 2014, 42, 578-605.	1.7	18
8	Financial risk of the Biotech Industry versus the Pharmaceutical Industry. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 155-165.	2.1	13
9	Do Firms Purposefully Change Capital Structure? Evidence from an Investment-Opportunity Shock to Drug Firms. <i>Journal of Financial and Quantitative Analysis</i> , 2021, 56, 915-944.	3.5	12
10	Strategic trading in the wrong direction by a large institutional insider. <i>Journal of Empirical Finance</i> , 2010, 17, 1-22.	1.8	8
11	The Conditional Performance of REIT Stock Repurchases. <i>Journal of Real Estate Finance and Economics</i> , 2006, 32, 129-149.	1.5	6
12	New estimates of pharmaceutical research and development spending by US-based firms from 1984 to 2003. <i>Managerial and Decision Economics</i> , 2007, 28, 481-483.	2.5	4
13	Measuring US Pharmaceutical Industry R&D Spending. <i>Pharmacoeconomics</i> , 2008, 26, 1005-1017.	3.3	4
14	How excluding some benefits from value assessment of new drugs impacts innovation. <i>Health Economics (United Kingdom)</i> , 2017, 26, 1813-1825.	1.7	3
15	Are the Insider Trades of a Large Institutional Investor Informed?. <i>Financial Review</i> , 2007, 42, 161-190.	1.8	1
16	Professor John Andrew Vernon 1968-2012. <i>Paediatric Drugs</i> , 2012, 14, 281-281.	3.1	0
17	Empirical Ross recovery without discretization. <i>Financial Review</i> , 0, , .	1.8	0